down arrow

Prestige Consumer Healthcare, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74112D1019
USD
60.06
-0.22 (-0.36%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

59.6960.25

52 Week

57.2590.04
Valuation
Technical
Day's Volume

CASH

128.41 k

Shareholding (Mar 2025)

FII

6.95%

Held by 120 FIIs

DII

33.61%

Held by 67 DIIs

Promoter

0.01%

How big is Prestige Consumer Healthcare, Inc.?

22-Jun-2025

As of Jun 18, Prestige Consumer Healthcare, Inc. has a market capitalization of $4.48 billion, with net sales of $1.14 billion and a net profit of $214.61 million over the latest four quarters.

Market Cap: As of Jun 18, Prestige Consumer Healthcare, Inc. has a market capitalization of 4,482.38 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 1,137.77 million and a net profit of 214.61 million.<BR><BR>Balance Sheet Snapshot: As of Mar 25, the company has shareholder's funds amounting to 1,834.90 million and total assets of 3,455.49 million.

Read More

What does Prestige Consumer Healthcare, Inc. do?

22-Jun-2025

Prestige Consumer Healthcare, Inc. markets and distributes over-the-counter healthcare products and operates in the small-cap Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $297 million and a net profit of $50 million, with a market cap of approximately $4.48 billion.

Overview:<BR>Prestige Consumer Healthcare, Inc. is engaged in the marketing, sales, and distribution of over-the-counter healthcare products within the Pharmaceuticals & Biotechnology industry and operates in the small-cap market.<BR><BR>Financial Snapshot:<BR>- Net Sales: 297 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 50 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 4,482.38 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 20.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.49<BR>- Return on Equity: 12.16%<BR>- Price to Book: 2.44<BR><BR>Contact Details:<BR>- Address: 660 White Plains Rd, TARRYTOWN NY: 10591-5139<BR>- Tel: 1 914 5246800<BR>- Website: http://prestigebrands.com

Read More

Who are in the management team of Prestige Consumer Healthcare, Inc.?

22-Jun-2025

As of March 2022, the management team of Prestige Consumer Healthcare, Inc. includes Mr. Ronald Lombardi as Chairman, President, and CEO, with Dr. Gary Costley as Lead Independent Director and several Independent Directors: Mr. John Byom, Mr. Christopher Coughlin, Ms. Sheila Hopkins, and Mr. James Jenness. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Prestige Consumer Healthcare, Inc. includes the following individuals:<BR><BR>- Mr. Ronald Lombardi serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Dr. Gary Costley is the Lead Independent Director.<BR>- Mr. John Byom, Mr. Christopher Coughlin, Ms. Sheila Hopkins, and Mr. James Jenness all serve as Independent Directors. <BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is Prestige Consumer Healthcare, Inc. technically bullish or bearish?

20-Sep-2025

As of July 31, 2025, Prestige Consumer Healthcare, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 with a year-to-date return of -17.92% compared to the S&P 500's 12.22%.

As of 31 July 2025, the technical trend for Prestige Consumer Healthcare, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the weekly MACD and moving averages, both showing bearish signals. The Bollinger Bands and KST also reflect a bearish trend on the weekly timeframe. The Dow Theory supports a mildly bearish outlook on both weekly and monthly periods. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -17.92% compared to the S&P 500's 12.22%, and a one-year return of -12.82% versus the S&P 500's 17.14%.

Read More

Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Prestige Consumer Healthcare, Inc. is considered overvalued with a shift in valuation grade from very attractive to attractive, reflected by high P/E, Price to Book, and EV to EBITDA ratios compared to peers, alongside a year-to-date return of -20.49% versus the S&P 500's 13.30% gain.

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA ratio of 14.39, all of which are higher than those of its peers. For instance, Alkermes Plc has a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium compared to its industry counterparts.<BR><BR>The company's recent performance shows a stark contrast to the broader market, with a year-to-date return of -20.49% compared to the S&P 500's gain of 13.30%. This underperformance, along with the high valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 3.13% and Operating profit at 3.08% over the last 5 years

 
2

Flat results in Jun 25

3

With ROCE of 12.76%, it has a fair valuation with a 1.99 Enterprise value to Capital Employed

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,511 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.46

stock-summary
Return on Equity

11.94%

stock-summary
Price to Book

1.89

Revenue and Profits:
Net Sales:
250 Million
(Quarterly Results - Jun 2025)
Net Profit:
47 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.02%
0%
-10.02%
6 Months
-29.17%
0%
-29.17%
1 Year
-30.02%
0%
-30.02%
2 Years
-0.81%
0%
-0.81%
3 Years
-5.99%
0%
-5.99%
4 Years
4.0%
0%
4.0%
5 Years
63.92%
0%
63.92%

Prestige Consumer Healthcare, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

Prestige Consumer Healthcare, Inc. has adjusted its valuation amid shifts in financial metrics and market standing within the Pharmaceuticals & Biotechnology sector. The company displays various profitability ratios and has faced performance challenges this year, contrasting with the broader market and highlighting the competitive landscape and differing risk profiles among peers.

Read More
Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62

Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 59.62 as of October 31, 2025. The company has seen a 7.75% decline over the past year, contrasting with the S&P 500's performance. Financial metrics show mixed results, with high institutional ownership and recent low quarterly sales figures.

Read More
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape

Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape

Prestige Consumer Healthcare, Inc. has adjusted its valuation, showcasing a P/E ratio of 20 and a price-to-book value of 2.48. The company demonstrates solid profitability with a ROCE of 12.76% and ROE of 12.16%, positioning it competitively within the pharmaceuticals and biotechnology sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.13%
EBIT Growth (5y)
3.08%
EBIT to Interest (avg)
5.29
Debt to EBITDA (avg)
3.40
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
0.40
Tax Ratio
24.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.87%
ROE (avg)
14.20%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.48
EV to EBIT
15.63
EV to EBITDA
14.39
EV to Capital Employed
1.99
EV to Sales
4.80
PEG Ratio
3.01
Dividend Yield
NA
ROCE (Latest)
12.76%
ROE (Latest)
12.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 92 Schemes (59.4%)

Foreign Institutions

Held by 120 Foreign Institutions (6.95%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -15.85% vs 2.14% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5.19% vs -17.87% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "249.50",
          "val2": "296.50",
          "chgp": "-15.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "79.40",
          "val2": "108.10",
          "chgp": "-26.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.20",
          "val2": "10.80",
          "chgp": "-5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-12.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.50",
          "val2": "50.10",
          "chgp": "-5.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "287.60%",
          "val2": "340.30%",
          "chgp": "-5.27%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 1.10% vs -0.20% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 2.53% vs 354.31% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,137.80",
          "val2": "1,125.40",
          "chgp": "1.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "379.40",
          "val2": "373.10",
          "chgp": "1.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "47.60",
          "val2": "67.20",
          "chgp": "-29.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "214.60",
          "val2": "209.30",
          "chgp": "2.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "307.00%",
          "val2": "304.30%",
          "chgp": "0.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
249.50
296.50
-15.85%
Operating Profit (PBDIT) excl Other Income
79.40
108.10
-26.55%
Interest
10.20
10.80
-5.56%
Exceptional Items
0.00
-12.50
100.00%
Consolidate Net Profit
47.50
50.10
-5.19%
Operating Profit Margin (Excl OI)
287.60%
340.30%
-5.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -15.85% vs 2.14% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -5.19% vs -17.87% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
1,137.80
1,125.40
1.10%
Operating Profit (PBDIT) excl Other Income
379.40
373.10
1.69%
Interest
47.60
67.20
-29.17%
Exceptional Items
-12.50
0.00
Consolidate Net Profit
214.60
209.30
2.53%
Operating Profit Margin (Excl OI)
307.00%
304.30%
0.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 1.10% vs -0.20% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 2.53% vs 354.31% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Prestige Consumer Healthcare, Inc. stock-summary
stock-summary
Prestige Consumer Healthcare, Inc.
Pharmaceuticals & Biotechnology
Prestige Consumer Healthcare Inc., formerly Prestige Brands Holdings, Inc. is engaged in the marketing, sales and distribution of over-the-counter healthcare products. The Company operates through two segments: North American Over-the-Counter (OTC) Healthcare, and International Over-the-Counter Healthcare. Its portfolio of OTC healthcare products includes core brands, such as DenTek specialty oral care products, Monistat women's health products, Nix lice treatment, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, The Doctor's NightGuard dental protector, Little Remedies pediatric over-the-counter products, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatment, BC and Goody's pain relievers, Beano gas prevention, Debrox earwax remover, and Gaviscon antacid.
Company Coordinates stock-summary
Company Details
660 White Plains Rd , TARRYTOWN NY : 10591-5139
stock-summary
Tel: 1 914 5246800
stock-summary
http://prestigebrands.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."